Full text
Earnings transcript
Read the complete earnings call transcript.
SGHT
Sight Sciences, Inc.
$3.52
-0.14
(-3.83%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 190.101M |
| Shares Outstanding: | 32.203M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Paul Badawi | |||||
| Full Time Employees: | 216 | |||||
| Address: |
| |||||
| Website: | https://www.sightsciences.com |
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company’s products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 81,056 | 79,866 | 77,363 |
| Gross Profit | 69,175 | 68,285 | 66,666 |
| EBITDA | -49,415 | -45,897 | -36,612 |
| Operating Income | -57,274 | -50,532 | -37,099 |
| Net Income | -55,547 | -51,507 | -38,426 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 166,651 | 142,839 | 115,300 |
| Total Liabilities | 46,436 | 55,316 | 51,358 |
| Total Stockholders Equity | 120,215 | 87,523 | 63,942 |
| Total Debt | 35,414 | 40,362 | 40,775 |
| Cash and Cash Equivalents | 138,129 | 120,357 | 91,965 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -47,184 | -22,351 | -29,694 |
| Capital Expenditure | -791 | -385 | -224 |
| Free Cash Flow | -47,975 | -22,736 | -29,918 |
| Net Income | -55,547 | -51,507 | -38,426 |
| Net Change in Cash | -46,871 | -17,772 | -28,127 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2028 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 105,018.663 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 105,018.670 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 105,018.667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 14,602.242 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 14,602.243 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 14,602.242 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -29,203.184 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -16,763.149 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -23,903.980 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 146,980.960 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 146,980.969 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 146,980.965 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -0.440 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -0.320 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -0.560 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 2 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about SGHT valuation
Is Sight Sciences, Inc. (SGHT) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Sight Sciences, Inc. (SGHT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is SGHT a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SGHT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is SGHT’s P/E ratio?
You can see SGHT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for SGHT?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is SGHT a good long-term investment?
Whether SGHT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
SGHT
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
-3.83
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 2.03 | Year High: | 9.24 | |
| Price Avg 50: | 4.89 | Price Avg 200: | 5.11 | |
| Volume: | 235086 | Average Volume: | 339006 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
